Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.
One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.
Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.
Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.
Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.
Oncternal Therapeutics announced updated interim data from the Phase 1/2 CIRLL study evaluating zilovertamab combined with ibrutinib for treating mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The overall response rate (ORR) for MCL was 85%, significantly outperforming historical data. For CLL, the ORR reached 91%, with a landmark progression-free survival (PFS) of 100% at 36 months for patients with specific prior therapies. Zilovertamab, targeting ROR1, showed a favorable safety profile, enhancing the company's confidence in moving towards a Phase 3 trial.
Oncternal Therapeutics (Nasdaq: ONCT) reported a robust business update on May 5, 2022, highlighting the upcoming initiation of the global Phase 3 study ZILO-301 for zilovertamab, targeting mantle cell lymphoma (MCL) in Q3 2022. The company plans to present interim data at ASCO 2022 for ongoing trials. A strategic partnership with Dana-Farber Cancer Institute was established to support CAR-T cell therapy ONCT-808. Moreover, ONCT-216 development was deprioritized, extending cash runway to Q3 2023 with $82.2 million in cash. The net loss for Q1 2022 was $9.9 million, or $0.20 per share.
Oncternal Therapeutics (Nasdaq: ONCT) announced the granting of an inducement award to new Clinical Data Manager, Samantha Carrington, on May 2, 2022. The award includes an option to purchase 20,000 shares of common stock, with a ten-year term and an exercise price based on the closing stock price on the grant date. The option vests over four years, with an initial 25% vesting after one year, followed by monthly installments. This award complies with Nasdaq's rules and aims to incentivize employees to join the company.
Oncternal Therapeutics (Nasdaq: ONCT) announced it will report its first quarter 2022 financial results on May 5, 2022, after market close. The management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a comprehensive business update. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, particularly in hematological malignancies and prostate cancer. Its clinical pipeline includes therapies such as zilovertamab and ONCT-808.
Oncternal Therapeutics (ONCT) announced the discontinuation of enrollment in the Phase 1/2 trial of ONCT-216 for Ewing sarcoma. The company is reallocating resources to focus on zilovertamab's Phase 3 study (ZILO-301), expected to start in Q3 2022, targeting mantle cell lymphoma (MCL). Oncternal also plans to submit an IND for its ROR1-targeting CAR-T therapy, ONCT-808, in mid-2022, alongside advancing the ONCT-534 program. With approximately $82.2 million in cash and no debt, the company expects to fund operations into Q3 2023.
Oncternal Therapeutics (Nasdaq: ONCT) announced the grant of an inducement award to Rachel Monet Kenny, the new Associate Director, CMC and Clinical Supply Chain, on April 1, 2022. The award includes an option to purchase 28,400 shares of common stock, vesting over four years. This move aligns with Nasdaq rules for employee incentives and aims to attract talent to support Oncternal’s focus on oncology therapies targeting unmet medical needs. The company continues to develop promising therapies like zilovertamab and ONCT-808 for various cancer treatments.
Oncternal Therapeutics announced progress in multiple clinical programs, including the Phase 3 Study ZILO-301 for treating relapsed or refractory mantle cell lymphoma (MCL) with zilovertamab and ibrutinib. Interim results exhibit an 81% objective response rate and a 35% complete response rate. The company also advanced ONCT-808 and ONCT-534 toward Investigational New Drug (IND) submissions. Financially, Oncternal reported a 2021 net loss of $31.3 million but maintains a robust cash position of $90.8 million, expected to sustain operations into mid-2023.
Oncternal Therapeutics (Nasdaq: ONCT) will release its Fourth Quarter and Full Year 2021 financial results on March 10, 2022, after U.S. markets close. A management webcast will follow at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results and provide a business update. The company is focused on developing oncology therapies for critical unmet medical needs and has a promising clinical pipeline, including zilovertamab and ONCT-808, targeting various cancers. Details are available at their investor website.
Oncternal Therapeutics (Nasdaq: ONCT) announced the granting of an inducement award to Susette Gorak as Senior Manager, Regulatory Affairs, effective March 1, 2022. This award includes an option to purchase 12,500 shares of ONCT common stock, vesting over four years. The grant complies with Nasdaq regulations and aims to attract talent to the company, which focuses on novel oncology therapies addressing critical unmet needs. Key developments include ongoing clinical trials for its drug candidates, including rivovertamab and ONCT-534, targeting various cancers.
Oncternal Therapeutics (Nasdaq: ONCT) will host a KOL webinar on January 25, 2022, focusing on treatment advancements for Mantle Cell Lymphoma (MCL) and advanced prostate cancer. KOL Michael Wang from MD Anderson will discuss MCL treatment and the Phase 3 study design for zilovertamab, which has FDA agreement. Evan Yu from Fred Hutch will present insights on next-gen treatments for prostate cancer, including ONCT-534. A Q&A session will follow the presentations. Zilovertamab is under investigation for MCL and CLL, while ONCT-534 targets resistant prostate cancer.
FAQ
What is the current stock price of Oncternal Therapeutics (ONCT)?
What is the market cap of Oncternal Therapeutics (ONCT)?
What does Oncternal Therapeutics specialize in?
What are the key products in Oncternal's pipeline?
What is zilovertamab?
What is ONCT-534?
How is Oncternal funded?
What makes ONCT-808 unique?
What is the significance of ONCT-216?
What are the current clinical trials for Oncternal's products?
Where can I find more information about Oncternal Therapeutics?
How does Oncternal aim to address unmet medical needs?
